First-in-class, orally bioavailable KRASG12V(ON) tri-complex inhibitors, as single agents and in combinations, drive profound anti-tumor activity in preclinical models of KRASG12V mutant cancers

E.S. Koltun, J. Cregg, M.A. Rice, D.M. Whalen, R. Freilich, J. Jiang,  R. Hansen, A. Bermingham, J.E. Knox, J. Dinglasan, K.J. Seamon, C, Blaj, S.S. Chang, Y.Liu, J. Huang, K-J. Chou, L. McDowell, B.J. Lee, D. Wildes, Z.P. Wang, M. Singh, A.L. Gill, J.A.M. Smith


American Association for Cancer Research Annual Meeting 2021, Virtual Meeting I; April 10-15, 2021.  Poster 1260.


Return to Media Home